| |
| | Clinical Trial: Internleukin-1 Trap to Treat Autoinflammatory Disease |
 | | Patients are seen at NIH at 3, 6, 9, and 12 months and are checked at home by telephone at months 1, 2, 4, 5, 7, 8, 10, 11, and 13 for a review of their general health, side effects, and other medications. |
 | | This exploratory study aims to examine the utility of the experimental drug candidate, IL 1 Trap (Regeneron Pharmaceuticals, Inc.) in the treatment of adult subjects with the autoinflammatory disorders Neonatal Onset Multisystem Inflammatory Disease (NOMID), Muckle-Wells Syndrome (MWS), and Familial Cold Autoinflammatory Syndrome (FCAS), Familial Mediterranean Fever (FMF), and adult Still's disease. |
 | | De Benedetti F, Pignatti P, Massa M, Sartirana P, Ravelli A, Martini A. Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. |
| www.clinicaltrials.gov /ct/show/NCT00094900 (1935 words) |
|